Liquidia (NASDAQ:LQDA) Insider Rajeev Saggar Sells 9,926 Shares

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 9,926 shares of the business’s stock in a transaction that occurred on Monday, July 13th. The stock was sold at an average price of $71.51, for a total transaction of $709,808.26. Following the transaction, the insider owned 171,799 shares of the company’s stock, valued at $12,285,346.49. This trade represents a 5.46% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Trading Up 7.4%

Shares of NASDAQ:LQDA opened at $76.49 on Wednesday. Liquidia Corporation has a 52 week low of $14.04 and a 52 week high of $82.96. The company’s 50 day moving average is $66.37 and its two-hundred day moving average is $47.52. The company has a market cap of $6.80 billion, a PE ratio of 546.40 and a beta of 0.55. The company has a current ratio of 2.22, a quick ratio of 2.03 and a debt-to-equity ratio of 1.18.

Liquidia (NASDAQ:LQDA) last issued its earnings results on Monday, May 11th. The company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to the consensus estimate of $119.44 million. The company’s revenue was up 4187.1% on a year-over-year basis. Equities analysts predict that Liquidia Corporation will post 3.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Bank of America restated a “neutral” rating and set a $79.00 price objective (up from $64.00) on shares of Liquidia in a research report on Monday, June 29th. BTIG Research lifted their price target on shares of Liquidia from $59.00 to $109.00 and gave the stock a “buy” rating in a research note on Monday, June 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a research report on Tuesday, April 21st. Wells Fargo & Company upped their price objective on shares of Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research note on Tuesday, May 12th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 price objective on shares of Liquidia in a report on Monday, May 11th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Liquidia has a consensus rating of “Moderate Buy” and a consensus price target of $68.88.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia in the fourth quarter valued at $25,000. NewEdge Advisors LLC purchased a new stake in shares of Liquidia in the second quarter valued at about $25,000. FNY Investment Advisers LLC acquired a new stake in shares of Liquidia during the third quarter worth about $34,000. Covestor Ltd grew its holdings in shares of Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after buying an additional 359 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in shares of Liquidia by 281.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,679 shares of the company’s stock worth $83,000 after buying an additional 4,927 shares during the last quarter. 64.54% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Recent commentary notes that Liquidia’s Yutrepia has had a strong commercial debut, suggesting early traction in its pulmonary arterial hypertension market opportunity. Can LQDA’s Yutrepia Drive Growth in the Competitive PAH Market?
• Neutral Sentiment: An investor letter from Laughing Water Capital mentioned Liquidia in a broader portfolio update, but did not provide a clear company-specific catalyst. Here’s Laughing Water Capital’s Updates on Liquidia Corp. (LQDA)
• Negative Sentiment: Multiple insiders, including the CEO, CFO, general counsel, and other executives, sold shares on July 13 in pre-arranged 10b5-1 transactions tied to tax withholding from vesting equity awards. While these sales were planned and not necessarily a bearish signal, the size and breadth of the sales may still pressure investor sentiment. SEC filing – Roger Jeffs sale

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).